187 filings
Page 2 of 10
8-K
yk7z0f
22 Mar 23
Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results
8:18am
8-K
cn6we nw9c7
16 Mar 23
Departure of Directors or Certain Officers
4:05pm
8-K
lkes l68ibl6vy14jju
26 Jan 23
Amendments to Articles of Incorporation or Bylaws
4:16pm
8-K
oi73fd12 lhgabcstoc
13 Dec 22
Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million
7:30am
8-K
uv9ceeu9yy635g5t
22 Nov 22
Marker Therapeutics Announces FDA Clearance of IND for MT-601, its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer
7:15am
8-K
1tjjexyabatpri 95
10 Nov 22
Marker Therapeutics Reports Q3 2022 Operating and Financial Results
4:16pm
8-K
xadq moxhm9mrb8b507m
20 Oct 22
Termination of a Material Definitive Agreement
4:31pm
8-K
97s 76wr44
27 Sep 22
Departure of Directors or Certain Officers
8:45am
8-K
fp15gfmt
13 Sep 22
Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker’s Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML
9:16am
8-K
ze20i
19 Aug 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:30am
8-K
iyrtuhl6nb61
11 Aug 22
Marker Therapeutics Reports Q2 2022 Operating and Financial Results
4:41pm
8-K
ps0gyrchhr12db22m
4 Aug 22
Company expects to initiate Phase 1 trial of MT-601 in r/r NHL in 2023
4:50pm
8-K
hf68ruvjk z6dpi
27 May 22
Amendments to Articles of Incorporation or Bylaws
4:06pm
8-K
ma4wyph1w06i14 azc7
13 May 22
Marker Therapeutics Reports Q1 2022 Operating and Financial Results
7:11am
8-K
ts9hmmmz3ps6
26 Apr 22
Marker Therapeutics Announces Entry into Services Agreement with Wilson Wolf
7:24am
8-K
xn7n2 4nf28we34y
6 Apr 22
Departure of Directors or Certain Officers
4:08pm
8-K
38d0ih1zm5
17 Mar 22
Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results
6:21pm
8-K
a47zh4tiiqkk5lyx9
18 Feb 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
8-K
zckdu1xajrqwt3a 2iu
16 Feb 22
Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion
4:32pm
8-K
2na77gc1ve
20 Jan 22
Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Pancreatic Cancer
12:00am